Thuy Bui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thuy Bui has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Dooley
3 shared publications- Alex Konstantatos
Anaesthesia and Perioperative Medicine Department Alfred Health Melbourne Australia
2 shared publications - Linda Velta Graudins
Pharmacy Department Alfred Health Melbourne Australia
2 shared publications - Paul Stewart Myles
Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia
2 shared publications - Aaron Drovandi
University of Manchester
1 shared publication - Aaron Woods
Pharmacy Department Alfred Health Melbourne Australia
1 shared publication
Latest Publications
- 1 October 2025
- Published by Springer Nature
- p. 75-98
Perioperative Medication Considerations for the Older Person
- 1 October 2025
- Published by Springer Nature
- p. 75-98
Perioperative Medication Considerations for the Older Person
- Open Access
- 15 May 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (3) , e1286
Trajectories of new opioid use after hip fracture surgery: a population-based cohort study
Introduction: The global annual incidence of hip fractures is projected to double over the next 20 to 30 years. The rates and risk factors for new persistent opioid use after hip fracture surgery remain poorly quantified. Objective: To describe trajectories, rates, and risk factors for new persistent opioid use after hip fracture surgery in Australia. Methods: A retrospective population-based cohort study was conducted using linked administrative health data in Australia. Adults aged ≥30 years discharged from hospital after a first hip fracture surgery between July 2012 and June 2017, opioid-naïve on admission, and alive 12 months postdischarge were included. Group-based trajectory modelling was utilised to determine trajectories and rates of opioid use 12 months postdischarge. Multivariate multinomial logistic regression analysis was performed to identify risk factors for persistent opioid use. Results: Among 10,309 opioid-naïve patients who had first hip fracture surgery, 5305 (51.5%) used opioids postdischarge. Opioid users were categorised as 58.9% (3127/5305) nonpersistent, 12.6% (670/5305) fluctuating, 12.1% (641/5305) late discontinuation, and 16.3% (867/5305) persistent. Key risk factors for persistent use were total oral morphine equivalent >600 mg in first 30 days postdischarge (relative risk [RR] 13.61, 95% confidence interval [CI] 9.34–19.83), transdermal opioid in the first 30 days postdischarge (RR 7.64, 95% CI 5.61–10.39), and hospital length of stay >60 days (RR 4.31, 95% CI 3.02–6.15). Conclusion: Among opioid-naïve patients, 16.3% were persistent opioid users at 12 months posthospital discharge. Future research should focus on targeted interventions to address modifiable risk factors to reduce new persistent opioid use in older and vulnerable populations.
- 15 May 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (3) , e1286
Open AccessTrajectories of new opioid use after hip fracture surgery: a population-based cohort study
Introduction: The global annual incidence of hip fractures is projected to double over the next 20 to 30 years. The rates and risk factors for new persistent opioid use after hip fracture surgery remain poorly quantified. Objective: To describe trajectories, rates, and risk factors for new persistent opioid use after hip fracture surgery in Australia. Methods: A retrospective population-based cohort study was conducted using linked administrative health data in Australia. Adults aged ≥30 years discharged from hospital after a first hip fracture surgery between July 2012 and June 2017, opioid-naïve on admission, and alive 12 months postdischarge were included. Group-based trajectory modelling was utilised to determine trajectories and rates of opioid use 12 months postdischarge. Multivariate multinomial logistic regression analysis was performed to identify risk factors for persistent opioid use. Results: Among 10,309 opioid-naïve patients who had first hip fracture surgery, 5305 (51.5%) used opioids postdischarge. Opioid users were categorised as 58.9% (3127/5305) nonpersistent, 12.6% (670/5305) fluctuating, 12.1% (641/5305) late discontinuation, and 16.3% (867/5305) persistent. Key risk factors for persistent use were total oral morphine equivalent >600 mg in first 30 days postdischarge (relative risk [RR] 13.61, 95% confidence interval [CI] 9.34–19.83), transdermal opioid in the first 30 days postdischarge (RR 7.64, 95% CI 5.61–10.39), and hospital length of stay >60 days (RR 4.31, 95% CI 3.02–6.15). Conclusion: Among opioid-naïve patients, 16.3% were persistent opioid users at 12 months posthospital discharge. Future research should focus on targeted interventions to address modifiable risk factors to reduce new persistent opioid use in older and vulnerable populations.
- 15 February 2024
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 54 (1) , 74-93
Standard of practice in pain management for pharmacy services
- 15 February 2024
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 54 (1) , 74-93
Standard of practice in pain management for pharmacy services
- Open Access
- 24 May 2023
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 53 (4) , 200-203
Time for change: improving neuromuscular blocking agent safety in Australia
Incidents involving mis‐selection and administration of neuromuscular blocking agents (NMBAs) leading to patient harm resulted in the initiation of activity in Victorian hospitals to review the management of this high‐risk group of medicines. Local risk mitigation strategies, such as in‐house labelling and restricting access, were considered partially effective, but it was recognised that a national approach was required. In 2015, hospital pharmacists — together with anaesthetist colleagues and peak patient safety organisations — made a submission to the Therapeutic Goods Administration (TGA) describing safety risks with NMBAs, with recommendations for improved NMBA labelling. This report describes the five‐year process which eventually led to the TGA mandating manufacturers to place alert labelling on NMBA products. As a result of this effort, a Victorian Therapeutics Advisory Group (VicTAG) grant enabled the development of a ‘NMBA Safer Practice Advisory Tool for Australian Hospitals’, providing a standard guide to monitor the safe use of NMBAs.
- 24 May 2023
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 53 (4) , 200-203
Open AccessTime for change: improving neuromuscular blocking agent safety in Australia
Incidents involving mis‐selection and administration of neuromuscular blocking agents (NMBAs) leading to patient harm resulted in the initiation of activity in Victorian hospitals to review the management of this high‐risk group of medicines. Local risk mitigation strategies, such as in‐house labelling and restricting access, were considered partially effective, but it was recognised that a national approach was required. In 2015, hospital pharmacists — together with anaesthetist colleagues and peak patient safety organisations — made a submission to the Therapeutic Goods Administration (TGA) describing safety risks with NMBAs, with recommendations for improved NMBA labelling. This report describes the five‐year process which eventually led to the TGA mandating manufacturers to place alert labelling on NMBA products. As a result of this effort, a Victorian Therapeutics Advisory Group (VicTAG) grant enabled the development of a ‘NMBA Safer Practice Advisory Tool for Australian Hospitals’, providing a standard guide to monitor the safe use of NMBAs.
- 30 July 2022
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 52 (5) , 363-370
Appropriateness of gabapentinoid prescription for surgical and trauma pain in gabapentinoid‐naïve patients: a retrospective review
Background: The gabapentinoids pregabalin and gabapentin are not recommended for managing acute pain in the absence of neuropathic symptoms, but such use is prominent in this setting.Aim: To assess gabapentinoid prescribing practices for gabapentinoid‐naïve patients after surgery and trauma.Method: A retrospective review of surgical and trauma admissions at a large, Australian, tertiary teaching hospital for patients prescribed a gabapentinoid for the first time, from February 2019 to May 2019, inclusive.Results: One hundred and eighty‐nine of 5494 (3.4%) gabapentinoid‐naïve surgical and trauma inpatients were prescribed a gabapentinoid, with 110 of the 189 (58.2%) also discharged on a gabapentinoid. Of the 110 patients, 60 (54.5%) were prescribed a gabapentinoid for either non‐neuropathic pain or undocumented pain indication, and the remainder for neuropathic symptoms. Only 66 (60.0%) patients discharged with a gabapentinoid had a plan for further management such as de‐escalation or general practitioner follow‐up. Of the 67 prescriptions written for patients on discharge, 32 (47.8%) were written as non‐government subsidised prescriptions. Four patients considered at high risk of developing addictive behaviours were discharged on a gabapentinoid.Conclusion: In this study, initiation and maintenance of gabapentinoid therapy in previously naïve surgical and trauma patients was infrequent, although it was often prescribed for an unclear or non‐neuropathic indication with little provision of, or no information for, intended duration of use. This review provides an opportunity for further intervention at the transition of care to minimise inappropriate long‐term gabapentinoid use and could be used to facilitate further research evaluating the impact of hospital‐prescribed gabapentinoids in the community.
- 30 July 2022
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 52 (5) , 363-370
Appropriateness of gabapentinoid prescription for surgical and trauma pain in gabapentinoid‐naïve patients: a retrospective review
Background: The gabapentinoids pregabalin and gabapentin are not recommended for managing acute pain in the absence of neuropathic symptoms, but such use is prominent in this setting.Aim: To assess gabapentinoid prescribing practices for gabapentinoid‐naïve patients after surgery and trauma.Method: A retrospective review of surgical and trauma admissions at a large, Australian, tertiary teaching hospital for patients prescribed a gabapentinoid for the first time, from February 2019 to May 2019, inclusive.Results: One hundred and eighty‐nine of 5494 (3.4%) gabapentinoid‐naïve surgical and trauma inpatients were prescribed a gabapentinoid, with 110 of the 189 (58.2%) also discharged on a gabapentinoid. Of the 110 patients, 60 (54.5%) were prescribed a gabapentinoid for either non‐neuropathic pain or undocumented pain indication, and the remainder for neuropathic symptoms. Only 66 (60.0%) patients discharged with a gabapentinoid had a plan for further management such as de‐escalation or general practitioner follow‐up. Of the 67 prescriptions written for patients on discharge, 32 (47.8%) were written as non‐government subsidised prescriptions. Four patients considered at high risk of developing addictive behaviours were discharged on a gabapentinoid.Conclusion: In this study, initiation and maintenance of gabapentinoid therapy in previously naïve surgical and trauma patients was infrequent, although it was often prescribed for an unclear or non‐neuropathic indication with little provision of, or no information for, intended duration of use. This review provides an opportunity for further intervention at the transition of care to minimise inappropriate long‐term gabapentinoid use and could be used to facilitate further research evaluating the impact of hospital‐prescribed gabapentinoids in the community.
- 16 July 2021
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 51 (4) , 342-347
AAA stewardship: managing high‐risk medications with dedicated antimicrobial, anticoagulation and analgesic stewardship programs
The first and most widely publicised pharmaceutical stewardship program has been for antimicrobials. Lack of care with antimicrobial management is a recognised risk to both patient and community safety. The core components of antimicrobial stewardship (AMS) can also be applied to other high‐risk medications, such as anticoagulants and analgesics. The authors discuss the implementation of anticoagulation and analgesic stewardship programs, based on the local AMS program principles, together forming the Antimicrobial, Anticoagulation, Analgesic (AAA) program. Amalgamated stewardship programs that focus on improving patient safety and optimising clinical outcomes beyond antimicrobials should be encouraged and adopted.
- 16 July 2021
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 51 (4) , 342-347
AAA stewardship: managing high‐risk medications with dedicated antimicrobial, anticoagulation and analgesic stewardship programs
The first and most widely publicised pharmaceutical stewardship program has been for antimicrobials. Lack of care with antimicrobial management is a recognised risk to both patient and community safety. The core components of antimicrobial stewardship (AMS) can also be applied to other high‐risk medications, such as anticoagulants and analgesics. The authors discuss the implementation of anticoagulation and analgesic stewardship programs, based on the local AMS program principles, together forming the Antimicrobial, Anticoagulation, Analgesic (AAA) program. Amalgamated stewardship programs that focus on improving patient safety and optimising clinical outcomes beyond antimicrobials should be encouraged and adopted.